Supplementary Tables – Impact of fast-track regulatory designations on strategic commercialisation decisions for autologous cell therapies

Supplementary Material 1. Early-access designations in the US, EU, Japan and China Supplementary Material 3. Distance between cities in miles Supplementary Material 5. Case study parameters Supplementary Material 6. Facility parameters Supplementary Material 7. Equipment Supplementary Material 8. Additional parameters